<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369729</url>
  </required_header>
  <id_info>
    <org_study_id>20-003732</org_study_id>
    <nct_id>NCT04369729</nct_id>
  </id_info>
  <brief_title>Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache</brief_title>
  <official_title>A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache - Human Studies Protocol: Individual Projects Excluding Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Genomics Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a United States Department of Defense funded Focused Program study that aims to&#xD;
      identify mechanisms and predictors for persistent of post-traumatic headache attributed to&#xD;
      mild traumatic brain injury, and identify methods of preventing post-traumatic headache&#xD;
      persistence&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The human studies component of this Focused Program include clinical phenotyping,&#xD;
      neurophysiology, molecular and genetic biomarker discovery, and brain imaging. This data will&#xD;
      be utilized to characterize post-traumatic headache and build univariate and multivariate&#xD;
      predictive models for post-traumatic headache persistence and for the response to&#xD;
      post-traumatic headache treatment. Some participants might be eligible to participate in the&#xD;
      clinical trial portion of this study.The clinical trial is a double-blind, randomized,&#xD;
      placebo-controlled investigation of erenumab for the treatment of post-traumatic headache.&#xD;
      Participants will be randomized when PTH has been present for 35-56 days. The clinical trial&#xD;
      component of this Focused Program is described in more detail in a separate&#xD;
      clinicaltrials.gov record.&#xD;
&#xD;
      Follow-up questionnaires, headache diary data, pain threshold results, and brain imaging data&#xD;
      will be collected longitudinally during the trial to assess for changes over time and&#xD;
      associations of such changes with post-traumatic headache treatment outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal Assessment of PTH Phenotype</measure>
    <time_frame>baseline with longitudinal follow-up at weeks four and sixteen</time_frame>
    <description>descriptive analysis of post-traumatic headache characteristics such as headache frequency and severity, and characteristics of associated conditions such as symptoms of sensory hypersensitivities, anxiety, depression, insomnia, autonomic dysfunction, and cognitive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Assessment of Cutaneous Pain Thresholds</measure>
    <time_frame>baseline with longitudinal follow-up at weeks four and sixteen</time_frame>
    <description>heat pain thresholds on the skin determined by quantitative sensory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Assessment of Visual Pain Thresholds from Bright Light Exposure</measure>
    <time_frame>baseline with longitudinal follow-up at weeks four and sixteen</time_frame>
    <description>visual pain thresholds to different light intensities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Assessment of Brain MRI</measure>
    <time_frame>baseline with longitudinal follow-up at weeks four and sixteen</time_frame>
    <description>structural brain imaging to include measures such as cortical thickness, regional volumes, brain curvature, white matter tract integrity, and functional brain imaging measures such as resting state functional connectivity and pain-induced brain activation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Assessment of Blood Based Biomarkers</measure>
    <time_frame>baseline with longitudinal follow-up at weeks four and sixteen</time_frame>
    <description>blood-based biomarkers, including DNA and targeted serum proteins, associated with acute and persistent post-traumatic headache and response to therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Assessment of Post-traumatic Headache Biomarkers</measure>
    <time_frame>baseline with longitudinal follow-up at weeks four and sixteen</time_frame>
    <description>clinical characteristics, pain thresholds, and brain imaging features as described above that are associated with acute post-traumatic headache and persistent post-traumatic headache; that predict the persistent of post-traumatic headache; and that predict and measure treatment response</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Post-Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>Post-Traumatic Headache</arm_group_label>
    <description>Individuals who have post-traumatic headache attributed to mild traumatic brain injury according to ICHD-3 diagnostic criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Healthy controls will have no history of traumatic brain injury and no history of migraine or other headaches</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be enrolled from the Mayo Clinic and Phoenix VA Healthcare System&#xD;
        and from the surrounding region&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        POST-TRAUMATIC HEADACHE ELIGIBILITY CRITERIA&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of acute PTH attributed to mild traumatic injury to the head as&#xD;
             defined by the International Classification of Headache Disorders (ICHD-3).&#xD;
&#xD;
          -  PTH onset 7-28 days prior to the time of enrollment.&#xD;
&#xD;
          -  Adults 18-70 years of age.&#xD;
&#xD;
          -  Willing to maintain a headache diary.&#xD;
&#xD;
          -  Willing and able to return for follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Episodic tension-type headache, migraine, or other headaches with at least 4 headache&#xD;
             days/month on average over the 6 months prior to the mTBI resulting in PTH.&#xD;
&#xD;
          -  Previous history of chronic headache (i.e. at least 15 headache days/month) including&#xD;
             PPTH, chronic migraine, medication overuse headache, new daily persistent headache,&#xD;
             hemicrania continua, chronic tension-type headache.&#xD;
&#xD;
          -  Diminished decision-making capacity that in the investigator's opinion would interfere&#xD;
             with the person's ability to provide informed consent and complete study procedures.&#xD;
&#xD;
          -  Current or prior use of preventive medications for migraine or other primary headache&#xD;
             disorder.&#xD;
&#xD;
          -  Use of onabotulinumtoxinA in the head, neck or face region within 12 months of&#xD;
             screening.&#xD;
&#xD;
          -  During the 6 months before screening, use of opioids or barbiturates on at least 4&#xD;
             days per month.&#xD;
&#xD;
          -  Subjects who underwent an intervention or used a device (e.g., nerve blocks,&#xD;
             transcranial magnetic stimulation, vagal nerve stimulation, or electrical trigeminal&#xD;
             nerve stimulation) for headache.&#xD;
&#xD;
          -  History of major psychiatric disorder such as schizophrenia and bipolar disorder.&#xD;
&#xD;
          -  History or evidence of any unstable or clinically significant medical condition, that&#xD;
             in the opinion of the investigator, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures, or completion.&#xD;
&#xD;
          -  History of positive neuroimaging findings that indicate a moderate or severe TBI.&#xD;
&#xD;
          -  Contraindications to magnetic resonance imaging, including, but not limited to (only&#xD;
             for those individuals participating in the MRI portion of this research):&#xD;
&#xD;
               1. Metal implants&#xD;
&#xD;
               2. Aneurysm clips&#xD;
&#xD;
               3. Severe claustrophobia&#xD;
&#xD;
               4. Implanted electronic devices&#xD;
&#xD;
               5. Insulin or infusion pump&#xD;
&#xD;
               6. Cochlear/otologic/ear implant&#xD;
&#xD;
               7. Non-removable prosthesis&#xD;
&#xD;
               8. Implanted shunts/catheters&#xD;
&#xD;
               9. Certain intrauterine devices&#xD;
&#xD;
              10. Tattooed makeup&#xD;
&#xD;
              11. Body piercings that cannot be removed&#xD;
&#xD;
              12. Metal fragments&#xD;
&#xD;
              13. Wire sutures or metal staples&#xD;
&#xD;
          -  Factors that reduce MR image quality and interpretability (only for those individuals&#xD;
             participating in the MRI portion of this research):&#xD;
&#xD;
               1. Dental braces or other non-removable devices (e.g., retainers)&#xD;
&#xD;
               2. Prior brain surgery&#xD;
&#xD;
               3. Known brain MRI abnormality that in the investigator's opinion will significantly&#xD;
                  impact MRI data.&#xD;
&#xD;
          -  Sensory disorders that in the investigator's opinion might affect perception of&#xD;
             cutaneous thermal stimuli (e.g., peripheral neuropathy) (only for those individuals&#xD;
             undergoing pain threshold testing).&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Currently or within 90 days prior to screening: received treatment in another drug&#xD;
             study or an investigational device study.&#xD;
&#xD;
        HEALTHY CONTROL ELIGIBILITY CRITERIA&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18-70 years of age.&#xD;
&#xD;
          -  Willing and able to return for follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of traumatic brain injury.&#xD;
&#xD;
          -  History of migraine or other headaches (Tension-type headache up to an average of 3&#xD;
             days per month is allowed).&#xD;
&#xD;
          -  Diminished decision-making capacity that in the investigator's opinion would interfere&#xD;
             with the person's ability to provide informed consent and complete study procedures.&#xD;
&#xD;
          -  During the 6 months before screening, use of opioids or barbiturates on an average of&#xD;
             at least 4 days per month.&#xD;
&#xD;
          -  History of major psychiatric disorder such as schizophrenia and bipolar disorder.&#xD;
&#xD;
          -  History or evidence of any unstable or clinically significant medical condition, that&#xD;
             in the opinion of the investigator, would pose a risk to subject safety or interfere&#xD;
             with the study evaluation, procedures, or completion.&#xD;
&#xD;
          -  Contraindications to magnetic resonance imaging, including, but not limited to:&#xD;
&#xD;
               1. Metal implants&#xD;
&#xD;
               2. Aneurysm clips&#xD;
&#xD;
               3. Severe claustrophobia&#xD;
&#xD;
               4. Implanted electronic devices&#xD;
&#xD;
               5. Insulin or infusion pump&#xD;
&#xD;
               6. Cochlear/otologic/ear implant&#xD;
&#xD;
               7. Non-removable prosthesis&#xD;
&#xD;
               8. Implanted shunts/catheters&#xD;
&#xD;
               9. Certain intrauterine devices&#xD;
&#xD;
              10. Tattooed makeup&#xD;
&#xD;
              11. Body piercings that cannot be removed&#xD;
&#xD;
              12. Metal fragments&#xD;
&#xD;
              13. Wire sutures or metal staples&#xD;
&#xD;
          -  Factors that reduce MR image quality and interpretability:&#xD;
&#xD;
               1. Dental braces or other non-removable devices (e.g., retainers)&#xD;
&#xD;
               2. Prior brain surgery&#xD;
&#xD;
               3. Known brain MRI abnormality that in the investigator's opinion will significantly&#xD;
                  impact MRI data.&#xD;
&#xD;
          -  Sensory disorders that in the investigator's opinion might affect perception of&#xD;
             cutaneous thermal stimuli (e.g., peripheral neuropathy).&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Currently or within 90 days prior to screening: received treatment in another drug&#xD;
             study or an investigational device study&#xD;
&#xD;
          -  Has previously received any CGRP ligand or receptor targeted monoclonal antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Schwedt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teri Radam</last_name>
    <phone>480-342-3775</phone>
    <email>Radam.Teri@Mayo.Edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix VA Health Care System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Ross, PhD</last_name>
      <phone>602-277-5551</phone>
      <phone_ext>7982</phone_ext>
      <email>Katherine.Ross3@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Radam</last_name>
      <phone>480-342-3775</phone>
      <email>Radam.Teri@Mayo.Edu</email>
    </contact>
    <investigator>
      <last_name>Todd Schwedt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Radam</last_name>
      <phone>480-342-3775</phone>
      <email>Radam.Teri@Mayo.Edu</email>
    </contact>
    <investigator>
      <last_name>Todd Schwedt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Todd J. Schwedt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

